Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Company Overview

Vertex Pharmaceuticals is a global biotechnology company dedicated to discovering, developing and commercializing innovative therapies for serious diseases. Since its founding in 1989 by Dr. Joshua Boger, the company has been at the forefront of translating cutting-edge science into medicines that address underlying causes rather than just symptoms. Headquartered in Boston, Vertex maintains research and development sites and commercial operations across North America, Europe, Australia and Asia.

Vertex’s core business revolves around cystic fibrosis (CF), where its portfolio of small-molecule therapies—including ivacaftor, lumacaftor, tezacaftor and elexacaftor—has transformed treatment paradigms for patients with specific genetic mutations. Beyond CF, the company has broadened its pipeline to include programs in sickle cell disease, beta-thalassemia, pain management and APOL1-mediated kidney disease, leveraging approaches such as gene editing, messenger RNA technology and novel ion channel modulators.

Research partnerships and collaborations are central to Vertex’s strategy. The company has teamed with academic institutions and industry leaders in gene therapy and CRISPR technology to accelerate development timelines and expand its reach into new therapeutic areas. Manufacturing facilities in North America and Europe support both clinical supply and commercial production, ensuring scalability as programs advance.

Under the leadership of President and Chief Executive Officer Reshma Kewalramani, Vertex continues to invest heavily in R&D, with a focus on precision medicine and genetic disease research. The company’s long-term vision emphasizes sustainable growth through innovation, strategic alliances and a patient-centric approach to drug development.

Key Stats

• Today's Range: $456.77 to $470.34
• 50-Day Range: $421.16 to $509.50
• 52-Week Range: $377.85 to $519.88
• Volume: 1.10 million shs
• Average Volume: 1.42 million shs
• Market Capitalization: $119.76 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $511.62
• Consensus Rating: Moderate Buy

Vertex Pharmaceuticals Stock Analysis - MarketRank™

Vertex Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 119th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 13 buy ratings, 14 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.03%

Earnings Growth

Earnings for Vertex Pharmaceuticals are expected to grow by 12.03% in the coming year, from $15.63 to $17.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vertex Pharmaceuticals is -118.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vertex Pharmaceuticals is -118.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vertex Pharmaceuticals has a P/B Ratio of 7.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.57% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vertex Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vertex Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -3.12

Percentage of Shares Shorted

1.57% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently decreased by 8.62%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.28

News Sentiment

Vertex Pharmaceuticals has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for Vertex Pharmaceuticals this week, compared to 29 articles on an average week.

Search Interest

31 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.

MarketBeat Follows

18 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,084.00 in company stock.

Percentage Held by Insiders

Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VRTX Stock Analysis - Frequently Asked Questions

How have VRTX shares performed this year?

Vertex Pharmaceuticals' stock was trading at $402.70 at the start of the year. Since then, VRTX shares have increased by 15.8% and is now trading at $466.36.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Monday, May, 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by $0.23. Vertex Pharmaceuticals's quarterly revenue was up 2.6% on a year-over-year basis.
Read the conference call transcript.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Vertex Pharmaceuticals: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Who are Vertex Pharmaceuticals' major shareholders?

Top institutional shareholders of Vertex Pharmaceuticals include Atwood & Palmer Inc. (0.02%), Gradient Investments LLC (0.01%), LVM Capital Management Ltd. MI (0.01%) and E. Ohman J or Asset Management AB. Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Charles F Wagner Jr, Bruce I Sachs, Bastiano Sanna, David Altshuler, Carmen Bozic, Edward Morrow Atkinson III, Jonathan Biller, Jeffrey M Leiden, Kristen Ambrose, Joy Liu, Sangeeta N Bhatia and Yuchun Lee.
View institutional ownership trends.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), QUALCOMM (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VRTX
• CIK: 875320
• Web: www.vrtx.com
• Phone: (617) 341-6100
• Fax: 617-576-2109
• Employees: 6,100
• Year Founded: 1989

Price Target and Rating

• Average Stock Price Target: $511.62
• High Stock Price Target: $586.00
• Low Stock Price Target: $420.00
• Potential Upside/Downside: +9.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.54
• Research Coverage: 28 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 29.90
• P/E Growth: N/A
• Net Income: -$535.60 million
• Net Margins: -8.91%
• Pretax Margin: -2.70%
• Return on Equity: -3.36%
• Return on Assets: -2.42%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.65
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $11.02 billion
• Price / Sales: 10.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $63.72 per share
• Price / Book: 7.33

Miscellaneous

• Outstanding Shares: 256,800,000
• Free Float: 256,283,000
• Market Cap: $120.02 billion
• Optionable: Optionable
• Beta: 0.41